Development of new antidepressants.
Creating New Medicines for Depression
AI simplified
Abstract
A large number of novel antidepressants are currently undergoing clinical evaluation with dual mechanisms of action on various neurotransmitter receptors.
- Many antidepressants target multiple neurotransmitter receptors, including serotonin and noradrenergic systems.
- Mirtazapine exemplifies this dual action by disinhibiting serotonin and norepinephrine neurotransmission.
- Mirtazapine's antagonistic properties at serotonin-2 and serotonin-3 receptors may reduce side effects associated with traditional SSRIs.
- The concept of 'designer polypharmacy' aims to combine pharmacologic principles to enhance effectiveness and tolerability of new antidepressants.
AI simplified